Issues with the Use of Prostate-Specific Antigen as a Surrogate End Point in Hormone-Resistant Prostate Cancer

European Urology, Supplements

Volumn 8, Issue 1, 2009, Pages 13-19

  Newling, Don W W ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Hormone resistant prostate cancer; Prostate specific antigen; Surrogate end point

Indexed keywords

ATRASENTAN; BIOLOGICAL MARKER; CALCITRIOL; DOCETAXEL; ESTRAMUSTINE; MITOXANTRONE; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROVENGE;

ANTIGEN EXPRESSION; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL STUDY; CLINICAL TRIAL; COMORBIDITY; DISEASE ASSOCIATION; DISEASE MARKER; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; HORMONAL THERAPY; HORMONE RESISTANT PROSTATE CANCER; HUMAN; METHODOLOGY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRACTICE GUIDELINE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 58149149765     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2008.10.002     Document Type: Review

References (25)

1. Bartsch G., Horninger W., Klocker H., et al. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int 101 (2008) 809-816
2. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery E, Barry MJ. Screening, treatment, and prostate cancer mortality in the Seattle area and Connecticut: fifteen-year follow-up. J Gen Intern Med. In press. doi:10.1007/s11606-008-0785-8.
3. Prentice R.L. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8 (1989) 431-440
4. Collette L. Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials. Eur Urol 53 (2008) 6-9
5. Ramiah V., George D.J., and Armstrong A.J. Clinical endpoints for drug development in prostate cancer. Curr Opin Urol 18 (2008) 303-308
6. Collette L. Prostate cancer: prognostic factors, markers of outcome and design of clinical trials [dissertation]. Rotterdam, the Netherlands: Erasmus University; 2006.
7. Petrylak D.P., Ankerst D.P., Jiang C.S., et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 98 (2006) 516-521
8. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
9. de Wit R. Chemotherapy in hormone-refractory prostate cancer. BJU Int 101 Suppl 2 (2008) 11-15
10. Beer T.M., Ryan C.W., Venner P.M., et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 25 (2007) 669-674
11. Small E.J., Fratesi P., Reese D.M., et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18 (2000) 3894-3903
12. Lin A.M., Hershberg R.M., and Small E.J. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. Urol Oncol 24 (2006) 434-441
13. Carducci M.A., Padley R.J., Breul J., et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 21 (2003) 679-689
14. Carducci M.A., Saad F., Abrahamsson P.A., et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110 (2007) 1959-1966
15. James ND, Caty A, Borre M, et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomized, phase II trial. Eur Urol. In press. doi:10.1016/j.eururo.2008.11.002.
16. Loberg R.D., Fielhauer J.R., Pienta B.A., et al. Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer. Urology 62 Suppl 1 (2003) 128-133
17. Stege R.H., Tribukait B., Carlstrom K.A., Grande M., and Pousette A.H. Tissue PSA from fine-needle biopsies of prostatic carcinoma as related to serum PSA, clinical stage, cytological grade, and DNA ploidy. Prostate 38 (1999) 183-188
18. Punglia R.S., D'Amico A.V., Catalona W.J., Roehl K.A., and Kuntz K.M. Impact of age, benign prostatic hyperplasia, and cancer on prostate-specific antigen level. Cancer 106 (2006) 1507-1513
19. Sindhwani P., and Wilson C.M. Prostatitis and serum prostate-specific antigen. Curr Urol Rep 6 (2005) 307-312
20. Verhamme K.M.C., Dieleman J.P., Bleumink G.S., et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care-the Triumph project. Eur Urol 42 (2002) 323-328
21. Magri V., Trinchieri A., Montanari E., et al. Reduction of PSA values by combination pharmacological therapy in patients with chronic prostatitis: implications for prostate cancer detection. Arch Ital Urol Androl 79 (2007) 84-92
22. Konety B.R., Nguyen T.T., Brenes G., et al. Evaluation of the effect of spinal cord injury on serum PSA levels. Urology 56 (2000) 82-86
23. Dutkiewicz S., Stepien K., and Witeska A. Effect of digital rectal examination on plasma prostate-specific antigen (PSA). Int Urol Nephrol 28 (1996) 211-214
24. Scher H.I., Halabi S., Tannock I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26 (2008) 1148-1159
25. Foley R., Hollywood D., and Lawler M. Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease. Endocr Relat Cancer 11 (2004) 477-488